NKTR vs. SPY

In the year-to-date period, NKTR achieves a -22.10% return, which is significantly lower than SPY's 0.87% return. Over the past 10 years, NKTR has underperformed SPY with an annualized return of -24.34%, while SPY has yielded a comparatively higher 12.73% annualized return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Nektar Therapeutics (NKTR) and SPDR S&P 500 ETF (SPY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current NKTR Sharpe Ratio is -0.51, which is lower than the SPY Sharpe Ratio of 0.70. The chart below compares the historical Sharpe Ratios of NKTR and SPY, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

NKTR has not paid dividends to shareholders, while SPY's dividend yield for the trailing twelve months is around 1.22%.

The maximum NKTR drawdown since its inception was -99.61%, which is greater than SPY's maximum drawdown of -55.19%. Use the drawdown chart below to compare losses from any high point for NKTR and SPY.

Nektar Therapeutics (NKTR) has a higher volatility of 28.18% compared to SPDR S&P 500 ETF (SPY) at 4.86%. This indicates that NKTR's price experiences larger fluctuations and is considered to be riskier than SPY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.